Skip to content
value.today
Cabaletta Bio, Inc. logo

Cabaletta Bio, Inc.

CABA
$343 Mmarket cap on Oct 30, 2026-63.9% since Jan 2024
Compare
World rank
#14,222
Revenue
—
For year ending December-2025
Net income
$-168 M
SEC filing
Employees
156
As of December 31, 2025
SEC filing

Cabaletta Bio, Inc. in brief

Cabaletta Bio, Inc. is a listed company in the Biotechnology industry, based in Philadelphia, Pennsylvania, USA. Its market value was $343 M on 30 October 2026, which makes it the 14,222nd largest listed company in the world and the 2,783rd largest in the USA on this site. It employs about 156 people and Steven Nichtberger is its chief executive. Its shares trade under the symbol CABA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Cabaletta Bio, Inc.

We are a late clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Our proprietary CABA®, or Cabaletta Approach to B cell Ablation platform, focuses on the CARTA approach. CARTA refers to Chimeric Antigen Receptor T cells for Autoimmunity and is designed to potentially reset the immune system. Based on clinical data reported to date, we believe our CABA® platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.

From the company's annual report filed with the US SEC: read the report

Cabaletta Bio, Inc. timeline

2 events, 2018–2019
  1. 2018
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2019
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 25 October 2019; shares registered for exchange trading on 23 October 2019.

Events of Cabaletta Bio, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$256 M$512 M$769 M$1.0 B2020202120222023202420252026

World rank over time

▼ down 628 places since 2020
2020-01-01: #13622#13,62220202021-01-01: #13689#13,68920212022-01-07: #22679#22,67920222022-12-25: #16900#16,90020222023-07-30: #12667#12,66720232024-01-05: #8869#8,86920242026-03-08: #8315#8,31520262026-08-01: #12693#12,69320262026-10-08: #13370#13,37020262026-10-30: #14250#14,2502026

Rank in USA: #2,864 (Jan 2020) · #2,954 (Jan 2021) · #4,423 (Jan 2022) · #3,461 (Dec 2022) · #2,686 (Jul 2023) · #2,079 (Jan 2024) · #1,521 (Mar 2026) · #2,600 (Aug 2026) · #2,626 (Oct 2026) · #2,787 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.1×
Free cash flow yield
-38.6%
Net margin
—
Operating margin
—
Return on equity
-149.8%
Liabilities / assets
32.1%
Profit per employee
$-1.1 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-12M—FY18Fiscal year ending Dec 2019: revenue —, net income $-17M—FY19Fiscal year ending Dec 2020: revenue —, net income $-33M—FY20Fiscal year ending Dec 2021: revenue —, net income $-46M—FY21Fiscal year ending Dec 2022: revenue —, net income $-53M—FY22Fiscal year ending Dec 2023: revenue —, net income $-68M—FY23Fiscal year ending Dec 2024: revenue —, net income $-116M—FY24Fiscal year ending Dec 2025: revenue —, net income $-168M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-172M$-168M—
Dec 2024——$-125M$-116M—
Dec 2023——$-75M$-68M—
Dec 2022——$-54M$-53M—
Dec 2021——$-46M$-46M—
Dec 2020——$-34M$-33M—
Dec 2019——$-19M$-17M—
Dec 2018——$-6M$-12M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-131M$1M$-132M$-2.10—
Dec 2024$-88M$2M$-90M$-2.34—
Dec 2023$-54M$1M$-54M$-1.65—
Dec 2022$-46M$2M$-49M$-1.81—
Dec 2021$-34M$1M$-35M$-1.80—
Dec 2020$-27M$1M$-27M$-1.44—
Dec 2019$-16M$1M$-17M$-4.07$0.00
Dec 2018$-5M——$-6.87—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-33M—Dec ’24Three months to Mar 2025: revenue —, net income $-36M—Mar ’25Three months to Jun 2025: revenue —, net income $-45M—Jun ’25Three months to Sep 2025: revenue —, net income $-45M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-42M—Dec ’25Three months to Mar 2026: revenue —, net income $-44M—Mar ’26Three months to Jun 2026: revenue —, net income $-51M—Jun ’26Three months to Sep 2026: revenue —, net income $-53M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-53M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Cabaletta Bio, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-172 M
Net income
$-168 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$165 M
Total liabilities
$53 M
Total equity
$112 M

As of December-2025

Top 100 institutional investors in Cabaletta Bio, Inc.#

As of Sep 30, 2026
163 institutions held 188.7 M shares (about 87.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 57.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Cabaletta Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jennison Associates LLC25,145,918+5,112,188 (+25.52%)11.66%$48 MNov 16, 2026
2Bain Capital Life Sciences Investors, LLC21,209,188+3,967,743 (+23.01%)9.83%$41 MNov 16, 2026
3T. Rowe Price Investment Management, Inc.17,250,098-1,619,809 (-8.58%)8.00%$33 MNov 16, 2026
4BlackRock, Inc.14,381,113+3,626,412 (+33.72%)6.67%$28 MNov 13, 2026
5Adage Capital Partners GP, L.L.C.14,174,758+5,000,000 (+54.50%)6.57%$27 MNov 16, 2026
6State Street Corp8,053,077+213,772 (+2.73%)3.73%$15 MNov 12, 2026
7Vanguard Capital Management LLC7,144,758-82,260 (-1.14%)3.31%$14 MNov 13, 2026
8Price T Rowe Associates Inc /MD/6,235,788+1,817,114 (+41.12%)2.89%$12 MNov 16, 2026
9Woodline Partners LP5,200,642+1,000,500 (+23.82%)2.41%$10 MNov 16, 2026
10Alyeska Investment Group, L.P.4,500,000New2.09%$9 MNov 16, 2026
11Cormorant Asset Management, LP4,500,000-500,000 (-10.00%)2.09%$9 MNov 16, 2026
12Geode Capital Management, LLC4,276,647+817,183 (+23.62%)1.98%$8 MNov 6, 2026
13Goldman Sachs Group Inc4,267,406+2,055,581 (+92.94%)1.98%$8 MNov 16, 2026
14Citadel Advisors LLC2,710,391-811,721 (-23.05%)1.26%$5 MNov 16, 2026
15Heights Capital Management, Inc2,500,000+1,744,374 (+230.85%)1.16%$5 MNov 16, 2026
16Franklin Templeton Inc2,413,9370 (0.00%)1.12%$5 MNov 12, 2026
17Morgan Stanley2,351,096+1,005,570 (+74.73%)1.09%$5 MNov 13, 2026
18Opaleye Management Inc.2,321,602-1,542,198 (-39.91%)1.08%$4 MNov 16, 2026
19Vanguard Portfolio Management LLC2,279,377+861,269 (+60.73%)1.06%$4 MNov 13, 2026
20Qube Research & Technologies Ltd2,106,718+679,878 (+47.65%)0.98%$4 MNov 13, 2026
21Propel Bio Management, LLC2,049,471New0.95%$4 MNov 13, 2026
22Diametric Capital, LP1,872,614+1,737,016 (+1281.00%)0.87%$4 MNov 16, 2026
23UBS Group AG1,644,876+172,981 (+11.75%)0.76%$3 MNov 10, 2026
24Marshall Wace, LLP1,543,867-22,072 (-1.41%)0.72%$3 MNov 13, 2026
25FMR LLC1,498,801+1,482,873 (+9309.85%)0.69%$3 MNov 10, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Cabaletta Bio, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Northern Trust Corp1,298,836+291,734 (+28.97%)0.60%$2 MNov 16, 2026
27Sphera Funds Management LTD.1,263,612-65,400 (-4.92%)0.59%$2 MNov 16, 2026
28Cantor Fitzgerald, L. P.1,211,629-388,373 (-24.27%)0.56%$2 MNov 16, 2026
29Occam Crest Management LP1,190,000New0.55%$2 MNov 13, 2026
30Dimensional Fund Advisors LP1,189,152+221,957 (+22.95%)0.55%$2 MNov 4, 2026
31Vanguard Fiduciary Trust Co1,095,231+6,636 (+0.61%)0.51%$2 MNov 13, 2026
32Two Sigma Investments, LP1,036,927-374,004 (-26.51%)0.48%$2 MNov 16, 2026
33Nuveen, LLC1,030,976+384,631 (+59.51%)0.48%$2 MNov 10, 2026
34Schroder Investment Management Group870,268+13,631 (+1.59%)0.40%$2 MNov 16, 2026
35Ameriprise Financial Inc828,238+93 (+0.01%)0.38%$2 MNov 16, 2026
36Susquehanna Portfolio Strategies, LLC734,855+351,561 (+91.72%)0.34%$1 MNov 16, 2026
37Ikarian Capital, LLC700,0000 (0.00%)0.32%$1 MNov 16, 2026
38Burkehill Global Management, LP700,0000 (0.00%)0.32%$1 MNov 16, 2026
39Squarepoint Ops LLC698,145New0.32%$1 MNov 9, 2026
40TD Asset Management Inc651,472+260,000 (+66.42%)0.30%$1 MNov 13, 2026
41Millennium Management LLC640,361-1,428,130 (-69.04%)0.30%$1 MNov 16, 2026
42Simplify Asset Management Inc.556,235New0.26%$1 MOct 27, 2026
43Stonepine Capital Management, LLC520,000-397,100 (-43.30%)0.24%$1 MNov 13, 2026
44Superstring Capital Management LP517,412-761,240 (-59.53%)0.24%$1 MNov 16, 2026
45Charles Schwab Investment Management Inc514,582+139,696 (+37.26%)0.24%$1 MNov 16, 2026
46KVP Capital Advisors, LP505,4310 (0.00%)0.23%$1 MNov 16, 2026
47Gsa Capital Partners LLP475,720-192,843 (-28.84%)0.22%$1 MNov 16, 2026
48XTX Topco Ltd466,072+420,370 (+919.81%)0.22%$1 MNov 16, 2026
49Bank Of America Corp /de/430,489-62,825 (-12.74%)0.20%$1 MNov 16, 2026
50Mackenzie Financial Corp416,161New0.19%$1 MNov 2, 2026
51Raiffeisen Bank International AG400,000-30,000 (-6.98%)0.19%$1 MOct 28, 2026
52Wellington Management Group LLP389,099+102,887 (+35.95%)0.18%$1 MNov 16, 2026
53Manufacturers Life Insurance Company, The385,775+203,720 (+111.90%)0.18%$1 MNov 13, 2026
54Bank of New York Mellon Corp384,738+79,919 (+26.22%)0.18%$1 MNov 5, 2026
55Barclays PLC334,450+289,749 (+648.19%)0.15%$1 MNov 6, 2026
56US Bancorp \de\273,107+256,614 (+1555.90%)0.13%$1 MNov 5, 2026
57Renaissance Technologies LLC272,700-1,262,600 (-82.24%)0.13%$1 MNov 12, 2026
58Invesco Ltd.249,498+7,933 (+3.28%)0.12%$0 MNov 12, 2026
59Susquehanna International Group, LLP245,275+182,047 (+287.92%)0.11%$0 MNov 16, 2026
60Rafferty Asset Management, LLC214,615+68,508 (+46.89%)0.10%$0 MNov 13, 2026
61Los Angeles Capital Management LLC195,544+161,125 (+468.13%)0.09%$0 MNov 12, 2026
62Boothbay Fund Management, LLC182,4550 (0.00%)0.08%$0 MNov 16, 2026
63Panagora Asset Management Inc157,953-3,963 (-2.45%)0.07%$0 MNov 12, 2026
64Rhumbline Advisers156,850+25,210 (+19.15%)0.07%$0 MNov 10, 2026
65BNP Paribas Financial Markets152,959+133,350 (+680.04%)0.07%$0 MNov 12, 2026
66Deutsche Bank AG\139,880+28,918 (+26.06%)0.06%$0 MNov 6, 2026
67Prelude Capital Management, LLC132,617+122,528 (+1214.47%)0.06%$0 MNov 16, 2026
68Alliancebernstein L.P.108,4100 (0.00%)0.05%$0 MNov 16, 2026
69Virtus Investment Advisers, LLC105,427-3,276 (-3.01%)0.05%$0 MNov 12, 2026
70Almitas Capital LLC103,860-22,040 (-17.51%)0.05%$0 MNov 17, 2026
71LPL Financial LLC102,953+23,878 (+30.20%)0.05%$0 MNov 6, 2026
72EntryPoint Capital, LLC102,763+51,836 (+101.78%)0.05%$0 MNov 13, 2026
73Bridgeway Capital Management, LLC98,875-168,497 (-63.02%)0.05%$0 MNov 16, 2026
74Citigroup Inc98,076-86,156 (-46.76%)0.05%$0 MNov 4, 2026
75MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.95,474+26,882 (+39.19%)0.04%$0 MNov 16, 2026
76MetLife Investment Management, LLC94,772+28,023 (+41.98%)0.04%$0 MNov 16, 2026
77Jpmorgan Chase & Co93,226+33,858 (+57.03%)0.04%$0 MNov 12, 2026
78Letko, Brosseau & Associates Inc90,4750 (0.00%)0.04%$0 MNov 6, 2026
79Empowered Funds, LLC85,675New0.04%$0 MNov 13, 2026
80AQR Capital Management LLC80,840New0.04%$0 MNov 16, 2026
81Point72 Asset Management, L.P.78,671New0.04%$0 MNov 16, 2026
82Profund Advisors LLC75,960+2,551 (+3.48%)0.04%$0 MOct 29, 2026
83ExodusPoint Capital Management, LP74,961New0.03%$0 MNov 16, 2026
84Graham Capital Management, L.P.74,755-6,524 (-8.03%)0.03%$0 MNov 16, 2026
85Brevan Howard Capital Management LP74,106New0.03%$0 MNov 16, 2026
86Creative Planning72,256New0.03%$0 MNov 2, 2026
87Persistent Asset Partners Ltd60,466+55,823 (+1202.30%)0.03%$0 MNov 13, 2026
88Grey Ledge Advisors, LLC60,000+30,000 (+100.00%)0.03%$0 MNov 2, 2026
89Vanguard Global Advisers, LLC58,153+781 (+1.36%)0.03%$0 MNov 13, 2026
90Matauro, LLC55,1080 (0.00%)0.03%$0 MNov 3, 2026
91Universal- Beteiligungs- und Servicegesellschaft mbH54,0860 (0.00%)0.03%$0 MNov 10, 2026
92Ieq Capital, LLC53,978New0.03%$0 MNov 10, 2026
93Quadrature Capital Ltd50,137New0.02%$0 MNov 13, 2026
94Police & Firemen's Retirement System of New Jersey47,368+14,165 (+42.66%)0.02%$0 MNov 9, 2026
95Wells Fargo & Company/mn47,286-149,586 (-75.98%)0.02%$0 MNov 16, 2026
96Virtu Financial LLC46,626-22,885 (-32.92%)0.02%$0 MNov 17, 2026
97Engineers Gate Manager LP41,085New0.02%$0 MNov 16, 2026
98ADAR1 Capital Management, LLC40,000-10,000 (-20.00%)0.02%$0 MNov 16, 2026
99Keybank National Association/oh39,0050 (0.00%)0.02%$0 MNov 4, 2026
100Simplex Trading, LLC37,310New0.02%$0 MNov 4, 2026

All 163 institutional investors, with who bought and sold →

Mutual funds holding Cabaletta Bio, Inc.#

114 funds hold shares worth $152 M (about 28.8% of the company). Since their previous reports 97 added shares and 4 sold, buying $94 M net.
Mutual funds holding Cabaletta Bio, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.7.87 M$24 M4.7%0.23%+36%Jun 30, 2026
🇺🇸 PGIM Jennison Health Sciences FundPGIM INVESTMENTS LLC4.96 M$19 M3.0%1.4%+41%May 29, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.5.26 M$16 M3.1%0.15%newJun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.5.22 M$16 M3.1%<0.01%+84%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors2.93 M$9 M1.8%0.01%newJun 30, 2026
🇺🇸 PGIM Jennison Small Company FundPrudential Jennison Small Co Fund, Inc.2.70 M$8 M1.6%0.24%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.1.88 M$6 M1.1%<0.01%+71%Jun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.1.80 M$6 M1.1%0.05%+195%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Stock Fund, Inc.T. Rowe Price Associates, Inc.1.39 M$4 M0.83%0.05%newJun 30, 2026
🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc.1.37 M$4 M0.82%0.03%newJun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC1.23 M$3 M0.74%<0.01%newJul 31, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.01 M$3 M0.60%0.03%+59%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC662,486$3 M0.40%<0.01%+8.2%May 31, 2026
🇺🇸 Franklin Biotechnology Discovery FundFranklin Advisers, Inc.876,846$2 M0.52%0.20%newJul 31, 2026
🇺🇸 T. Rowe Price Institutional Small-Cap Stock FundT. Rowe Price Associates, Inc.746,576$2 M0.45%0.05%newJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors523,569$2 M0.31%0.01%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors486,921$2 M0.29%<0.01%newJun 30, 2026
🇺🇸 Small Cap Value PortfolioMason Street Advisors, LLC485,013$2 M0.29%0.23%+52%Jun 30, 2026
🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC496,689$1 M0.30%<0.01%newJul 31, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.448,514$1 M0.27%<0.01%newJul 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors373,752$1 M0.22%0.08%+60%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC279,599$1 M0.17%<0.01%+61%May 31, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP334,526$1 M0.20%<0.01%no changeJul 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC224,492$1 M0.13%<0.01%+62%May 31, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.303,059$1 M0.18%0.08%newJul 31, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP301,437$1 M0.18%<0.01%no changeJul 31, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.274,359$1 M0.16%<0.01%newJul 31, 2026
🇺🇸 PGIM Jennison Blend FundPGIM INVESTMENTS LLC192,216$1 M0.11%0.06%newMay 29, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC210,446$1 M0.13%0.01%newJun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.202,673$1 M0.12%0.04%newJun 30, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC178,606$0 M0.11%0.10%newJul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC172,727$0 M0.10%0.02%−7.4%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC149,656$0 M0.09%<0.01%newJul 31, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC122,955$0 M0.07%0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC122,675$0 M0.07%0.26%no changeJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.110,667$0 M0.07%0.05%+149%Jun 30, 2026
🇺🇸 Small Company Value TrustJohn Hancock Variable Trust Advisers LLC108,215$0 M0.06%0.22%+54%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Value Insights FundGoldman Sachs Asset Management, L.P.115,487$0 M0.07%0.02%newJul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.113,690$0 M0.07%<0.01%+125%Jul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation82,200$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC67,179$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC93,819$0 M0.06%<0.01%+89%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC77,990$0 M0.05%0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.76,892$0 M0.05%<0.01%+49%Jun 30, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP80,701$0 M0.05%<0.01%no changeJul 31, 2026
🇺🇸 Goldman Sachs Small Cap Growth Insights FundGoldman Sachs Asset Management, L.P.66,996$0 M0.04%0.06%newJul 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.57,487$0 M0.03%<0.01%+17%Jun 30, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Growth Allocation FundT. Rowe Price Associates, Inc.47,082$0 M0.03%<0.01%newMay 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.55,350$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC53,371$0 M0.03%0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC60,355$0 M0.04%<0.01%+80%Jul 31, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS51,836$0 M0.03%0.07%newJun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.48,754$0 M0.03%0.07%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors46,561$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC53,547$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC44,710$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC44,710$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC44,137$0 M0.03%0.01%newJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC42,068$0 M0.03%0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.38,100$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC37,844$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC37,200$0 M0.02%0.05%+1606%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC32,378$0 M0.02%0.01%newJun 30, 2026
🇺🇸 AST PGIM Aggressive Multi-Asset PortfolioAST Investment Services, Inc.30,758$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.30,249$0 M0.02%<0.01%+99%Jun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC26,242$0 M0.02%0.05%+2383%Jun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC25,212$0 M0.02%0.04%+54%Jun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS25,098$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC23,375$0 M0.01%0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC25,464$0 M0.02%0.02%+75%Jul 31, 2026
🇺🇸 AVIP BlackRock Advantage Small Cap Growth PortfolioCONSTELLATION INVESTMENTS INC21,833$0 M0.01%0.05%newJun 30, 2026
🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust17,404$0 M0.01%<0.01%−78%May 31, 2026
🇺🇸 T. Rowe Price Spectrum Moderate Allocation FundT. Rowe Price Associates, Inc.17,019$0 M0.01%<0.01%newMay 31, 2026
🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP22,315$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC18,071$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.17,651$0 M0.01%0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC19,980$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.17,171$0 M0.01%0.01%newJun 30, 2026
🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP17,765$0 M0.01%<0.01%no changeJul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC15,250$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.14,700$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.16,490$0 M<0.01%<0.01%+71%Jul 31, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC13,592$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Spectrum Conservative Allocation FundT. Rowe Price Associates, Inc.11,160$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP15,719$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Avantis U.S. Small Cap Equity FundAmerican Century ETF Trust9,741$0 M<0.01%0.03%no changeMay 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC13,183$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management10,217$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC9,002$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC8,841$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS9,987$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.8,572$0 M<0.01%<0.01%−7.9%Jun 30, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC8,596$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC8,511$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC7,785$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC6,148$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC5,179$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC5,084$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC4,836$0 M<0.01%0.01%newJun 30, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS5,304$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Cabaletta Bio, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$296 K
8 purchases, 8 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$296 K
open market only
Insiders on file
15
since
$296 K-$241 K$0Nov 2023: bought $0 (0 trades), sold $196 K (2 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $241 K (2 trades)DecJan 2024: bought $0 (0 trades), sold $215 K (2 trades)Jan 24Jan 2026: bought $296 K (8 trades), sold $0 (0 trades)Jan 26
Bought (open market)Sold (open market)Hover a month for the totals
Cabaletta Bio, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed David J. ChangChief Medical OfficerBuy+8,800$2.260$20 K8,800Form 4
filed Catherine BollardDirectorBuy+4,405$2.270$10 K5,405Form 4
filed Michael GerardGeneral CounselBuy+6,600$2.270$15 K6,600Form 4
filed Shawn TomaselloDirectorBuyindirect+22,725$2.210$50 K22,725Form 4
filed Mark SimonDirectorBuy+11,061$2.280$25 K147,205Form 4
filed Steven NichtbergerPresident & CEO, DirectorBuy+45,000$2.240$101 K1.03 MForm 4
filed Steve GavelChief Commercial OfficerBuy+22,170$2.270$50 K22,170Form 4
filed Gwendolyn BinderPresident, Science & Tech.Buy+11,312$2.190$25 K31,312Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Cabaletta Bio, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
38.4 M
38.2% of shares · 8.19 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1.49 reverse split

Trading halts

  • 2024-11-29 14:38 UTC, code LUDP, resumed 14:43 UTC

Fails to deliver

  • : 35,869 shares at $1.59
  • : 100 shares at $1.52
  • : 1 shares at $1.41
  • : 3,695 shares at $1.97
  • : 809 shares at $2.02

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cabaletta Bio, Inc. scorecard#

Passes 1 of the 12 checks that could be worked out: strongest in financial health (1 of 3), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.1×Price to book 3.1× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-38.6%Free cash flow is -38.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.10 vs -2.34Diluted EPS -2.10 in fiscal 2025 against -2.34 the year before (report's currency).
    • ✗Net income higher than five years earlier-$168 M-$168 M in fiscal 2025 against -$33 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$168 MNet income -$168 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-127.0%-127.0% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities2.8×Current ratio 2.77 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-86.1×Operating income -86.1 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Cabaletta Bio, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cabaletta Bio, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Research and development1439755393221124.5
General and administrative3028191514127.01.7
Operating expenses17212575544634196.2
Operating income−172−125−75−54−46−34−19−6.2
Interest and finance income6.0107.01.20.00.51.70.2
Interest expense and finance costs2.00.70—————
Income tax00——————
Net income including minority interests−168−116−68−53−46−33−17−12
Net income attributable to shareholders−168−116−68−53−46−33−17−12
Earnings per share, basic-2.10-2.34-1.65-1.81-1.80-1.44-4.07-6.87
Earnings per share, diluted-2.10-2.34-1.65-1.81-1.80-1.44-4.07-6.87
Shares, weighted average (basic)——1.25.9————
Dividends per share——————0.00—
Balance sheet
Cash and cash equivalents831641938212210113633
Short-term investments510482507.2——
Other current assets5.32.73.22.32.34.94.31.0
Current assets13916724410912511414134
Property, plant and equipment1.92.72.52.61.40.90.8—
Right-of-use (leased) assets3.46.34.95.00———
Total assets16518525411712611514134
Accounts payable6.64.94.52.52.31.20.90.6
Current liabilities5027169.58.45.23.10.9
Lease liabilities (non-current)02.41.53.00———
Total liabilities533317128.4———
Retained earnings−517−349−233−166−113−66−33−12
Shareholders' equity112152236105118110138−11
Total liabilities and equity16518525411712611514134
Shares outstanding1005148292924243.8
Cash-flow statement
Share-based compensation2119116.95.84.42.30.6
Cash from operating activities−131−88−54−46−34−27−16−4.7
Capital expenditure−1.2−2.2−0.7−2.5−1.2−0.6−0.7—
Cash from investing activities−5047−22−276.0−8.0−0.7—
Shares issued940r1853348−0.271—
Cash from financing activities100121883349−0.012038
Exchange-rate effect on cash0.0−0.00—————
Change in cash−81−29112—————
Report10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Where Cabaletta Bio, Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 3 subsidiaries on file.

Cabaletta Bio, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office1 subsidiary—
🇩🇪 Germany1 subsidiary—
🇨🇭 Switzerland1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Cabaletta Bio, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.9 M
Steven Nichtberger
Other top executives, average
$973 K
the CEO earned 2× this
$100 invested is now
$24
Cabaletta Bio, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Steven Nichtberger$1.9 M$1.7 M$973 K$24
2024Steven Nichtberger$8.1 M−$8.6 M$3.4 M$25
2023Steven Nichtberger$4.8 M$14.5 M$2.2 M$245

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Cabaletta Bio, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 1 · Material agreement 2 · Agreement ended 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 10

Cabaletta Bio, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Material agreementResults announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Bylaws or fiscal year changedShareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Cabaletta Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$50 MNo. 2$50 to $250 million16equitySEC
Oct 2018$38 MNo. 1$10 to $50 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Cabaletta Bio, Inc.#

$50 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.

Lobbying, 2025
$50 K
#1,359 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
—
  • Medicare/Medicaid2 reports

Lobbying firms hired in 2025

Hogan Lovells US LLP $50 K

Cabaletta Bio, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2025$50 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Cabaletta Bio”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Cabaletta Bio, Inc. compares in Biotechnology

  • Market cap$343 M · higher than 53% of 726
  • Price / book3.1× · lower than 48% of 534
  • FCF yield-38.6% · higher than 29% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cabaletta Bio, Inc.🇺🇸$343 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cabaletta Bio, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cabaletta Bio, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cabaletta Bio, Inc.? Suggest a correction